Raquel Seruca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6631061/publications.pdf

Version: 2024-02-01

211 papers 14,357 citations

63 h-index 24258 110 g-index

212 all docs

 $\begin{array}{c} 212 \\ \text{docs citations} \end{array}$

times ranked

212

13773 citing authors

#	Article	IF	CITATIONS
1	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 2003, 22, 4578-4580.	5.9	616
2	Helicobacter pylori and Interleukin 1 Genotyping: An Opportunity to Identify High-Risk Individuals for Gastric Carcinoma. Journal of the National Cancer Institute, 2002, 94, 1680-1687.	6.3	563
3	Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology, 2002, 123, 1804-1811.	1.3	535
4	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1 </i> mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479
5	A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology, 2003, 125, 364-371.	1.3	450
6	Early Gastric Cancer in Young, Asymptomatic Carriers of Germ-Line E-Cadherin Mutations. New England Journal of Medicine, 2001, 344, 1904-1909.	27.0	420
7	Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology, 2001, 121, 823-829.	1.3	402
8	The prevalence of PIK3CA mutations in gastric and colon cancer. European Journal of Cancer, 2005, 41, 1649-1654.	2.8	314
9	Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncology, The, 2015, 16, e60-e70.	10.7	311
10	Model of the early development of diffuse gastric cancer in Eâ€cadherin mutation carriers and its implications for patient screening. Journal of Pathology, 2004, 203, 681-687.	4.5	242
11	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	10.7	237
12	Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites., 1998, 21, 101-107.		203
13	Characterization of a Recurrent Germ Line Mutation of the E-Cadherin Gene: Implications for Genetic Testing and Clinical Management. Clinical Cancer Research, 2005, 11, 5401-5409.	7.0	187
14	Germline CDH1 deletions in hereditary diffuse gastric cancer families. Human Molecular Genetics, 2009, 18, 1545-1555.	2.9	185
15	Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Human Molecular Genetics, 2003, 12, 575-582.	2.9	167
16	BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene, 2005, 24, 3995-3998.	5.9	155
17	Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Human Mutation, 2002, 19, 510-517.	2.5	153
18	Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Letters, 2009, 281, 162-170.	7.2	153

#	Article	IF	CITATIONS
19	Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 367-378.	2.8	148
20	Somatic Mutations and Deletions of the E-Cadherin Gene Predict Poor Survival of Patients With Gastric Cancer. Journal of Clinical Oncology, 2013, 31, 868-875.	1.6	145
21	The Clinicopathological Features of Gastric Carcinomas with Microsatellite Instability May Be Mediated by Mutations of Different "Target Genes― American Journal of Pathology, 1998, 153, 1211-1219.	3.8	144
22	Quantification of Epigenetic and Genetic 2nd Hits in CDH1 During Hereditary Diffuse Gastric Cancer Syndrome Progression. Gastroenterology, 2009, 136, 2137-2148.	1.3	142
23	Genetics, Pathology, and Clinics of Familial Gastric Cancer. International Journal of Surgical Pathology, 2006, 14, 21-33.	0.8	141
24	lonizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities. Scientific Reports, 2016, 6, 18765.	3.3	139
25	Epithelial E- and P-cadherins: Role and clinical significance in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 297-311.	7.4	137
26	BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene, 2003, 22, 9192-9196.	5.9	132
27	Modulation of E-cadherin function and dysfunction by N-glycosylation. Cellular and Molecular Life Sciences, 2011, 68, 1011-1020.	5.4	132
28	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer. European Journal of Cancer, 2012, 48, 2941-2953.	2.8	129
29	Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Human Molecular Genetics, 2004, 13, 2303-2311.	2.9	127
30	Lack of microRNAâ€101 causes Eâ€cadherin functional deregulation through EZH2 upâ€regulation in intestinal gastric cancer. Journal of Pathology, 2012, 228, 31-44.	4.5	125
31	BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer, 2008, 8, 255.	2.6	124
32	<i>Helicobacter pylori</i> Infection Induces Genetic Instability of Nuclear and Mitochondrial DNA in Gastric Cells. Clinical Cancer Research, 2009, 15, 2995-3002.	7.0	123
33	Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. International Journal of Cancer, 1995, 64, 32-36.	5.1	110
34	E-cadherin and adherens-junctions stability in gastric carcinoma: Functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2690-2700.	2.4	101
35	The role of N-acetylglucosaminyltransferase III and ν in the post-transcriptional modifications of E-cadherin. Human Molecular Genetics, 2009, 18, 2599-2608.	2.9	100
36	Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Human Molecular Genetics, 2010, 19, 943-952.	2.9	100

#	Article	IF	CITATIONS
37	Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. Genes Chromosomes and Cancer, 2001, 32, 136-143.	2.8	99
38	Candidate driver genes in microsatelliteâ€unstable colorectal cancer. International Journal of Cancer, 2012, 130, 1558-1566.	5.1	99
39	E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. European Journal of Cancer, 2004, 40, 1897-1903.	2.8	97
40	Gastric cancer: adding glycosylation to the equation. Trends in Molecular Medicine, 2013, 19, 664-676.	6.7	95
41	Loss and Recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation Is a Mechanism Involved in Epithelial-Mesenchymal-Epithelial Transitions. PLoS ONE, 2012, 7, e33191.	2.5	93
42	Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene, 2004, 23, 2236-2240.	5.9	92
43	Helicobacter pylori Induces Gastric Epithelial Cell Invasion in a c-Met and Type IV Secretion System-dependent Manner. Journal of Biological Chemistry, 2006, 281, 34888-34896.	3.4	92
44	Oncogenic mutations in gastric cancer with microsatellite instability. European Journal of Cancer, 2011, 47, 443-451.	2.8	92
45	Docosahexaenoic Acid Inhibits Helicobacter pylori Growth In Vitro and Mice Gastric Mucosa Colonization. PLoS ONE, 2012, 7, e35072.	2.5	90
46	CagA Associates with câ€Met, Eâ€Cadherin, and p120â€Catenin in a Multiproteic Complex That Suppresses <i>Helicobacter pylori </i> à€"Induced Cellâ€Invasive Phenotype. Journal of Infectious Diseases, 2009, 200, 745-755.	4.0	89
47	Loss of Heterozygosity and Promoter Methylation, but not Mutation, May Underlie Loss of TFF1 in Gastric Carcinoma. Laboratory Investigation, 2002, 82, 1319-1326.	3.7	88
48	ActivatedBRAFtargets proximal colon tumors with mismatch repair deficiency and MLH1 in activation. Genes Chromosomes and Cancer, 2004, 39, 138-142.	2.8	87
49	The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell–cell adhesion and to suppress invasion. Oncogene, 2003, 22, 5716-5719.	5.9	81
50	EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. Human Molecular Genetics, 2007, 16, 1639-1647.	2.9	81
51	E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. Human Molecular Genetics, 2003, 12, 3007-3016.	2.9	79
52	The novel colorectal cancer biomarkers <i>CDO1, ZSCAN18</i> and <i>ZNF331</i> are frequently methylated across gastrointestinal cancers. International Journal of Cancer, 2015, 136, 844-853.	5.1	76
53	Eâ€cadherin dysfunction in gastric cancer ―Cellular consequences, clinical applications and open questions. FEBS Letters, 2012, 586, 2981-2989.	2.8	74
54	Clinical spectrum and pleiotropic nature of <i>CDH1</i> germline mutations. Journal of Medical Genetics, 2019, 56, 199-208.	3.2	74

#	Article	IF	CITATIONS
55	Microbial-based therapy of cancer: Current progress and future prospects. Bioengineered Bugs, 2010, 1, 178-190.	1.7	72
56	The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC. European Journal of Human Genetics, 2013, 21, 301-309.	2.8	72
57	E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. European Journal of Cancer, 2011, 47, 631-639.	2.8	69
58	Specific Clinical and Biological Features Characterize Inflammatory Bowel Disease–Associated Colorectal Cancers Showing Microsatellite Instability. Journal of Clinical Oncology, 2007, 25, 4231-4238.	1.6	68
59	Pâ€cadherin functional role is dependent on Eâ€cadherin cellular context: a proof of concept using the breast cancer model. Journal of Pathology, 2013, 229, 705-718.	4.5	68
60	Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. Journal of Medical Genetics, 2018, 55, 431-441.	3.2	68
61	Causes and consequences of microsatellite instability in gastric carcinogenesis. World Journal of Gastroenterology, 2014, 20, 16433.	3.3	67
62	A model to infer the pathogenic significance of CDH1 germline missense variants. Journal of Molecular Medicine, 2006, 84, 1023-1031.	3.9	66
63	Hereditary gastric cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 147-157.	2.4	66
64	De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Laboratory Investigation, 2010, 90, 1604-1614.	3.7	66
65	Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. Journal of Pathology, 2001, 194, 358-366.	4.5	65
66	B-RafV600E Cooperates With Alternative Spliced Rac1b to Sustain Colorectal Cancer Cell Survival. Gastroenterology, 2008, 135, 899-906.	1.3	65
67	MSI phenotype and MMR alterations in familial and sporadic gastric cancer. International Journal of Cancer, 2011, 128, 1606-1613.	5.1	65
68	E-cadherin mutations and cell motility: A genotype–phenotype correlation. Experimental Cell Research, 2009, 315, 1393-1402.	2.6	64
69	P-cadherin role in normal breast development and cancer. International Journal of Developmental Biology, 2011, 55, 811-822.	0.6	64
70	Pâ€Cadherin Is Coexpressed with CD44 and CD49f and Mediates Stem Cell Properties in Basalâ€ike Breast Cancer. Stem Cells, 2012, 30, 854-864.	3.2	64
71	Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. Human Molecular Genetics, 2008, 17, 3566-3576.	2.9	62
72	The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression. Cells, 2020, 9, 394.	4.1	60

#	Article	IF	CITATIONS
73	Helicobacter pylori infection generates genetic instability in gastric cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 58-65.	7.4	59
74	Eâ€cadherin deregulation in breast cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 5930-5936.	3.6	59
75	Identification of germline mutations in the cancer predisposing gene CDH1 in patients with orofacial clefts. Human Molecular Genetics, 2013, 22, 919-926.	2.9	55
76	NOD2/CARD15 and TNFA, But Not ILLB and ILLRN, are Associated With Crohn $\hat{E}^{1}/4$ s Disease. Inflammatory Bowel Diseases, 2005, 11, 331-339.	1.9	54
77	Colorectal cancer and RASSF familyâ€"A special emphasis on RASSF1A. International Journal of Cancer, 2013, 132, 251-258.	5.1	54
78	Hyperplastic polyposis and diffuse carcinoma of the stomach. A study of a family. Cancer, 1993, 72, 323-329.	4.1	53
79	Cytogenetic findings in eleven gastric carcinomas. Cancer Genetics and Cytogenetics, 1993, 68, 42-48.	1.0	53
80	Promoter methylation of TGFÎ ² receptor I and mutation of TGFÎ ² receptor II are frequent events in MSI sporadic gastric carcinomas. Journal of Pathology, 2003, 200, 32-38.	4.5	53
81	BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying <i>BRAFSup><i>V</i>600<i>E</i> but not <i>KRAS</i> mutations. Journal of Pathology, 2008, 214, 320-327.</i>	4.5	53
82	E-Cadherin Destabilization Accounts for the Pathogenicity of Missense Mutations in Hereditary Diffuse Gastric Cancer. PLoS ONE, 2012, 7, e33783.	2.5	53
83	Target gene mutation profile differs between gastrointestinal and endometrial tumors with mismatch repair deficiency. Cancer Research, 2002, 62, 1609-12.	0.9	53
84	E-Cadherin Alterations in Hereditary Disorders with Emphasis on Hereditary Diffuse Gastric Cancer. Progress in Molecular Biology and Translational Science, 2013, 116, 337-359.	1.7	52
85	Blue intensity matters for cell cycle profiling in fluorescence DAPI-stained images. Laboratory Investigation, 2017, 97, 615-625.	3.7	52
86	Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Experimental Cell Research, 2005, 310, 99-104.	2.6	51
87	Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. Gut, 2010, 59, 1516-1526.	12.1	51
88	CLMP Is Required for Intestinal Development, and Loss-of-Function Mutations Cause Congenital Short-Bowel Syndrome. Gastroenterology, 2012, 142, 453-462.e3.	1.3	49
89	i(12p)-negative testicular germ cell tumors. Cancer Genetics and Cytogenetics, 1988, 35, 171-178.	1.0	48
90	E-cadherin germline mutation carriers: clinical management and genetic implications. Cancer and Metastasis Reviews, 2014, 33, 1081-1094.	5.9	48

#	Article	IF	CITATIONS
91	The interleukin-8-251*T/*A polymorphism is not associated with risk for gastric carcinoma development in a Portuguese population. European Journal of Cancer Prevention, 2008, 17, 28-32.	1.3	47
92	Predicting the Functional Impact of CDH1 Missense Mutations in Hereditary Diffuse Gastric Cancer. International Journal of Molecular Sciences, 2017, 18, 2687.	4.1	47
93	Genetic screening for hereditary diffuse gastric cancer. Expert Review of Molecular Diagnostics, 2003, 3, 201-215.	3.1	46
94	Identification of two distinct regions of deletion at 6q in gastric carcinoma. Genes Chromosomes and Cancer, 1995, 14, 28-34.	2.8	45
95	Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer. Cancer Genetics and Cytogenetics, 1995, 82, 140-145.	1.0	45
96	Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene, 2005, 24, 7630-7634.	5.9	45
97	Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer, 2008, 8, 10.	2.6	45
98	Rare Variants in the Epithelial Cadherin Gene Underlying the Genetic Etiology of Nonsyndromic Cleft Lip with or without Cleft Palate. Human Mutation, 2015, 36, 1029-1033.	2.5	45
99	Evidence of tumor microsatellite instability in gastric cancer with familial aggregation. Familial Cancer, 2009, 8, 215-220.	1.9	44
100	E-cadherin impairment increases cell survival through Notch-dependent upregulation of Bcl-2. Human Molecular Genetics, 2012, 21, 334-343.	2.9	44
101	MSI-L Gastric Carcinomas Share the hMLH1 Methylation Status of MSI-H Carcinomas but Not Their Clinicopathological Profile. Laboratory Investigation, 2000, 80, 1915-1923.	3.7	43
102	Helicobacter pylori infection affects mitochondrial function and DNA repair, thus, mediating genetic instability in gastric cells. Mechanisms of Ageing and Development, 2013, 134, 460-466.	4.6	43
103	<i>CPEB1</i> , a novel gene silenced in gastric cancer: a <i>Drosophila</i> approach. Gut, 2012, 61, 1115-1123.	12.1	41
104	Hereditary diffuse gastric cancer – Pathophysiology and clinical management. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 1055-1068.	2.4	40
105	Colorectal cancer-related mutant <i>KRAS</i> alleles function as positive regulators of autophagy. Oncotarget, 2015, 6, 30787-30802.	1.8	39
106	Role of pathology in the identification of hereditary diffuse gastric cancer: report of a Portuguese family. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 181-184.	2.8	38
107	Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors. Cancers, 2019, 11, 2010.	3.7	38
108	Microsatellite instability in hyperplastic and adenomatous polyps of the stomach., 1999, 86, 1649-1656.		37

#	Article	IF	CITATIONS
109	Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. Cancers, 2020, 12, 1598.	3.7	37
110	Role of site-specific promoter hypomethylation in aberrant MUC2 mucin expression in mucinous gastric carcinomas. Cancer Letters, 2003, 189, 129-136.	7.2	35
111	E-cadherin missense mutations, associated with hereditary diffuse gastric cancer (HDGC) syndrome, display distinct invasive behaviors and genetic interactions with the Wnt and Notch pathways in Drosophila epithelia. Human Molecular Genetics, 2006, 15, 1704-1712.	2.9	35
112	Tumor Necrosis Factor Alpha Extended Haplotypes and Risk of Gastric Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2416-2420.	2.5	35
113	<i>O</i> -mannosylation and <i>N</i> -glycosylation: two coordinated mechanisms regulating the tumour suppressor functions of E-cadherin in cancer. Oncotarget, 2016, 7, 65231-65246.	1.8	35
114	Genetic Screening for Familial Gastric Cancer. Hereditary Cancer in Clinical Practice, 2004, 2, 51.	1.5	34
115	?-Catenin (CTNNB1) gene amplification: A new mechanism of protein overexpression in cancer. Genes Chromosomes and Cancer, 2005, 42, 238-246.	2.8	34
116	CD44 alternative splicing in gastric cancer cells is regulated by culture dimensionality and matrix stiffness. Biomaterials, 2016, 98, 152-162.	11.4	34
117	Insulin/IGF-I Signaling Pathways Enhances Tumor Cell Invasion through Bisecting GlcNAc N-glycans Modulation. An Interplay with E-Cadherin. PLoS ONE, 2013, 8, e81579.	2.5	33
118	Karyotyping and DNA flow cytometry of an orchidoblastoma. Cancer Genetics and Cytogenetics, 1988, 36, 7-11.	1.0	30
119	Molecular targets and biological modifiers in gastric cancer. Seminars in Diagnostic Pathology, 2008, 25, 274-287.	1.5	30
120	Adherens junctions as targets of microorganisms: A focus on <i>Helicobacter pylori</i> . FEBS Letters, 2013, 587, 259-265.	2.8	30
121	The Bacterial Protein Azurin Impairs Invasion and FAK/Src Signaling in P-Cadherin-Overexpressing Breast Cancer Cell Models. PLoS ONE, 2013, 8, e69023.	2.5	30
122	Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation. British Journal of Cancer, 2015, 113, 686-692.	6.4	30
123	Mutant BRAF Induces DNA Strand Breaks, Activates DNA Damage Response Pathway, and Up-Regulates Glucose Transporter-1 in Nontransformed Epithelial Cells. American Journal of Pathology, 2012, 180, 1179-1188.	3.8	29
124	Familial gastric polyposis revisited. Cancer Genetics and Cytogenetics, 1991, 53, 97-100.	1.0	28
125	Detection of <i>N-myc</i> Amplification in Neuroblastomas Using Southern Blotting on Fine Needle Aspirates. Acta Cytologica, 2001, 45, 169-173.	1.3	28
126	Quantification of mutant E-cadherin using bioimaging analysis of in situ fluorescence microscopy. A new approach to CDH1 missense variants. European Journal of Human Genetics, 2015, 23, 1072-1079.	2.8	28

#	Article	IF	CITATIONS
127	E-cadherin-defective gastric cancer cells depend on Laminin to survive and invade. Human Molecular Genetics, 2015, 24, 5891-5900.	2.9	28
128	Patterns of \hat{l}^2 -Catenin Expression in Gastric Carcinoma: Clinicopathological Relevance and Mutation Analysis. International Journal of Surgical Pathology, 2003, 11, 1-9.	0.8	27
129	A malignant mixed gonadal stromal tumor of the testis with heterologous components and i(12p) in one of its metastases. Cancer Genetics and Cytogenetics, 1989 , 41 , 105 - 114 .	1.0	26
130	Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype. Cancer Genetics and Cytogenetics, 2008, 180, 110-114.	1.0	26
131	Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Human Molecular Genetics, 2010, 19, 697-706.	2.9	26
132	Crosstalk between Helicobacter pylori and Gastric Epithelial Cells Is Impaired by Docosahexaenoic Acid. PLoS ONE, 2013, 8, e60657.	2.5	26
133	Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. Journal of Medical Genetics, 2006, 44, 75-80.	3.2	25
134	High Incidence of Familial Gastric Cancer in Tuscany, a Region in Italy. Oncology, 2007, 72, 243-247.	1.9	25
135	Microsatellite instability in medullary breast carcinomas. , 1999, 82, 644-647.		24
136	Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer, 2009, 9, 387.	2.6	24
137	Helicobacter pylori's cholesterol uptake impacts resistance to docosahexaenoic acid. International Journal of Medical Microbiology, 2014, 304, 314-320.	3.6	24
138	C/EBPα expression is associated with homeostasis of the gastric epithelium and with gastric carcinogenesis. Laboratory Investigation, 2010, 90, 1132-1139.	3.7	23
139	Mononucleotide precedes dinucleotide repeat instability during colorectal tumour development in Lynch syndrome patients. Journal of Pathology, 2009, 219, 96-102.	4.5	22
140	Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). European Journal of Human Genetics, 2013, 21, 891-891.	2.8	22
141	High-throughput molecular profiling of a P-cadherin overexpressing breast cancer model reveals new targets for the anti-cancer bacterial protein azurin. International Journal of Biochemistry and Cell Biology, 2014, 50, 1-9.	2.8	22
142	Matrix metalloproteases as maestros for the dual role of LPS- and IL-10-stimulated macrophages in cancer cell behaviour. BMC Cancer, 2015, 15, 456.	2.6	22
143	Cytogenetics of a case of osteosarcoma. Cancer Genetics and Cytogenetics, 1988, 32, 149-151.	1.0	21
144	Frequent ki-ras mutations in gastric tumors of the MSI phenotype. Gastroenterology, 2003, 125, 1282-1283.	1.3	21

#	Article	IF	CITATIONS
145	ADP-Ribosylation Factor 6 Mediates E-Cadherin Recovery by Chemical Chaperones. PLoS ONE, 2011, 6, e23188.	2.5	21
146	Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 1187-1201.	3.4	21
147	Sequence Diversity at the Proximal 14q32.1 SERPIN Subcluster: Evidence for Natural Selection Favoring the Pseudogenization of SERPINA2. Molecular Biology and Evolution, 2006, 24, 587-598.	8.9	20
148	CCAAT/Enhancer Binding Protein \hat{l}^2 (C/EBP \hat{l}^2) Isoforms as Transcriptional Regulators of the Pro-Invasive CDH3/P-Cadherin Gene in Human Breast Cancer Cells. PLoS ONE, 2013, 8, e55749.	2.5	20
149	DNAJB4 molecular chaperone distinguishes WT from mutant E-cadherin, determining their fate in vitro and in vivo. Human Molecular Genetics, 2014, 23, 2094-2105.	2.9	20
150	Tetra-and pentanucleotide short tandem repeat instability in gastric cancer. Electrophoresis, 1997, 18, 1633-1636.	2.4	19
151	Helicobacter Pylori Targets the EPHA2 Receptor Tyrosine Kinase in Gastric Cells Modulating Key Cellular Functions. Cells, 2020, 9, 513.	4.1	19
152	Loss of Y chromosome in gastric carcinoma. Cancer Genetics and Cytogenetics, 1992, 61, 39-41.	1.0	18
153	Substantial reduction of the gastric carcinoma critical region at 6q16.3-q23.1., 1999, 26, 29-34.		18
154	Analysis of microsatellite instability in medulloblastoma. Neuro-Oncology, 2009, 11, 458-467.	1.2	18
155	Gastric Cardia Carcinoma is Associated with the Promoter -77T>C Gene Polymorphism of X-Ray Cross-Complementing Group 1 (XRCC1). Journal of Gastrointestinal Surgery, 2009, 13, 2233-2238.	1.7	18
156	ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPA in CDH3 gene activation. Human Molecular Genetics, 2010, 19, 2554-2566.	2.9	18
157	Intricate Macrophage-Colorectal Cancer Cell Communication in Response to Radiation. PLoS ONE, 2016, 11, e0160891.	2.5	18
158	The mechanisms underlying MMR deficiency in immunodeficiencyâ€related nonâ€Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. International Journal of Cancer, 2009, 125, 2360-2366.	5.1	17
159	CLMP Is Essential for Intestinal Development, but Does Not Play a Key Role in Cellular Processes Involved in Intestinal Epithelial Development. PLoS ONE, 2013, 8, e54649.	2.5	17
160	MBD4 mutations are rare in gastric carcinomas with microsatellite instability. Cancer Genetics and Cytogenetics, 2003, 145, 103-107.	1.0	16
161	<i>KRAS</i> Mutations and Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer With Lymph Node Metastases. Journal of Clinical Oncology, 2009, 27, 158-159.	1.6	16
162	Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesisâ€. Human Molecular Genetics, 2012, 21, 4253-4269.	2.9	16

#	Article	IF	CITATIONS
163	Quantification of topological features in cell meshes to explore E-cadherin dysfunction. Scientific Reports, 2016, 6, 25101.	3.3	16
164	Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2018, 1110, 35-53.	1.6	16
165	Dependence of Tensional Homeostasis on Cell Type and on Cell–Cell Interactions. Cellular and Molecular Bioengineering, 2018, 11, 175-184.	2.1	16
166	S100P is a molecular determinant of E-cadherin function in gastric cancer. Cell Communication and Signaling, 2019, 17, 155.	6.5	16
167	Cytogenetic study of a combined germ cell tumor of the testis. Cancer Genetics and Cytogenetics, 1988, 35, 159-165.	1.0	15
168	In vitro demonstration of intra-locus compensation using the ornithine transcarbamylase protein as model. Human Molecular Genetics, 2007, 16, 2209-2214.	2.9	15
169	Pathology and Genetics of Familial Gastric Cancer. International Journal of Surgical Pathology, 2010, 18, 33-36.	0.8	15
170	p53 alterations in gastric carcinoma:. Cancer Genetics and Cytogenetics, 1994, 75, 45-50.	1.0	14
171	A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 619-626.	2.8	14
172	Estrogens, MSI and Lynch syndrome-associated tumors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 194-200.	7.4	14
173	TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. Familial Cancer, 2009, 8, 383-390.	1.9	14
174	A novel CDH1 germline missense mutation in a sporadic gastric cancer patient in north-east of Italy. Clinical and Experimental Medicine, 2013, 13, 149-157.	3.6	14
175	SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells. Cell Communication and Signaling, 2018, 16, 75.	6.5	14
176	Genetics of hereditary diffuse gastric cancer: progress and future challenges. Future Oncology, 2006, 2, 363-370.	2.4	13
177	KRAS Signaling Pathway Alterations in Microsatellite Unstable Gastrointestinal Cancers. Advances in Cancer Research, 2010, 109, 123-143.	5.0	13
178	Integrin \hat{I}^21 orchestrates the abnormal cell-matrix attachment and invasive behaviour of E-cadherin dysfunctional cells. Gastric Cancer, 2022, 25, 124-137.	5.3	13
179	Cytogenetic study of a sclerosing stromal tumor of the ovary. Cancer Genetics and Cytogenetics, 1990, 49, 103-106.	1.0	12
180	Bilateral apocrine carcinoma of the breast Molecular and immunocytochemical evidence for two independent primary tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 433, 505-509.	2.8	12

#	Article	IF	CITATIONS
181	Mitochondrial DNA alteration in gastric cancer. Gastroenterology, 2000, 119, 1808-1809.	1.3	12
182	Unmasking the role of <i>KRAS </i> and <i>BRAF </i> pathways in MSI colorectal tumors. Expert Review of Gastroenterology and Hepatology, 2009, 3, 5-9.	3.0	12
183	Dissecting the signaling pathways associated with the oncogenic activity of MLK3 P252H mutation. BMC Cancer, 2014, 14, 182.	2.6	12
184	Extended structural variation of a pentanucleotide repeat in the GSTP1 gene: characterisation in a normal population and in thyroid and gastric tumours. European Journal of Human Genetics, 2000, 8, 540-544.	2.8	11
185	Allelic gains and losses in distinct regions of chromosome 6 in gastric carcinoma. Cancer Genetics and Cytogenetics, 2001, 131, 54-59.	1.0	11
186	WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas. Gastroenterology, 2003, 124, 270-271.	1.3	11
187	The germline CDH1 c.48 G > C substitution contributes to cancer predisposition through generation of a pro-invasive mutation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 770, 106-111.	1.0	11
188	Clinical and functional characterization of the CDH1 germline variant c.1679C>G in three unrelated families with hereditary diffuse gastric cancer. European Journal of Human Genetics, 2018, 26, 1348-1353.	2.8	11
189	E-cadherin signal sequence disruption: a novel mechanism underlying hereditary cancer. Molecular Cancer, 2018, 17, 112.	19.2	11
190	Clonal cytogenetic abnormalities and telomeric associations in a fibroxanthoma of the stomach. Genes Chromosomes and Cancer, 1992, 5, 407-409.	2.8	10
191	PCR amplification of DNA obtained from archived hematoxylin-eosin– and giemsa-stained breast cancer aspirates. Diagnostic Cytopathology, 1998, 19, 395-397.	1.0	10
192	New Target Genes in Endometrial Tumors Show a Role for the Estrogen-Receptor Pathway in Microsatellite-Unstable Cancers. Human Mutation, 2014, 35, 1514-1523.	2.5	10
193	Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden. Cancers, 2021, 13, 4359.	3.7	9
194	Specific inhibition of p110 \hat{i} subunit of PI3K: putative therapeutic strategy for <i>KRAS</i> mutant colorectal cancers. Oncotarget, 2016, 7, 68546-68558.	1.8	8
195	The Porto European Cancer Research Summit 2021. Molecular Oncology, 2021, 15, 2507-2543.	4.6	7
196	Germline Missense Mutants in Hereditary Diffuse Gastric Cancer. , 2013, , 77-86.		7
197	Proteomic Identification of a Gastric Tumor ECM Signature Associated With Cancer Progression. Frontiers in Molecular Biosciences, 2022, 9, 818552.	3.5	7
198	Familial gastric carcinoma. Diagnostic Histopathology, 2014, 20, 239-246.	0.4	6

#	Article	IF	CITATIONS
199	Geometric compensation applied to image analysis of cell populations with morphological variability: a new role for a classical concept. Scientific Reports, 2018, 8, 10266.	3.3	6
200	A machine learning approach for single cell interphase cell cycle staging. Scientific Reports, 2021, 11, 19278.	3.3	5
201	Bacterial protein azurin as a new candidate drug to treat untreatable breast cancers. , 2011, , .		3
202	Assessment of microsatellite alterations in young patients with gastric adenocarcinoma. Cancer, 1997, 80, 1357-1362.	4.1	2
203	E-Cadherin Radial Distribution Characterization for Mutation Detection Purposes. Lecture Notes in Computer Science, 2013, , 173-180.	1.3	2
204	Hereditary Gastric Cancer: A New Syndrome. Updates in Surgery Series, 2021, , 37-50.	0.1	2
205	Differential Impacts on Tensional Homeostasis of Gastric Cancer Cells Due to Distinct Domain Variants of E-Cadherin. Cancers, 2022, 14, 2690.	3.7	2
206	LETTER TO THE EDITOR. Relationship between the expression of p53 and the aggressiveness of gastric carcinoma. , 1997, 181, 349-349.		1
207	Microsatellite instability in hyperplastic and adenomatous polyps of the stomach. Cancer, 1999, 86, 1649-1656.	4.1	1
208	Hereditary Diffuse Gastric Cancer and Other Gastric Cancers Associated with Hereditary Predisposition Syndromes. Molecular Pathology Library, 2013, , 83-107.	0.1	0
209	PIK3CA Gene Alterations in Human Cancers. , 2009, , 1-20.		O
210	Non-CDH1-Associated Familial Gastric Cancer and Epigenetics Factors., 2013,, 111-125.		0
211	Capturing quantitative features of protein expression fromin situfluorescence microscopic images of cancer cell populations., 2017,, 279-297.		O